Stock FTRP FIELD TRIP HEALTH LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Field Trip Health Ltd. Canadian Securities Exchange

Equities

FTRP

CA31656R1029

End-of-day quote Canadian Securities Exchange
Other stock markets
 03:30:00 08/07/2021 am IST 		5-day change 1st Jan Change
6.65 CAD +6.40% Intraday chart for Field Trip Health Ltd. +0.36% +32.78%
20/05 Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of Re104 for Development in Depressive Disorders CI
02/05 Reunion Neuroscience Inc. Announces Advancing RE104, Its Proprietary, Clinical-Stage Serotonergic Psychedelic Drug Candidate to Provide Benefits to Patients with Underserved Mental Health Disorders CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of Re104 for Development in Depressive Disorders
CI
Reunion Neuroscience Inc. Announces Advancing RE104, Its Proprietary, Clinical-Stage Serotonergic Psychedelic Drug Candidate to Provide Benefits to Patients with Underserved Mental Health Disorders
CI
Reunion Neuroscience Inc. announced that it has received $103 million in funding from a group of investors
CI
Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate A Phase 2 Study of Re104 for the Treatment of Postpartum Depression
CI
Reunion Neuroscience Brief: Reunion and MPM BioImpact Complete Plan of Arrangement Effective Today, whereby MPM Acquired Reunion in an all-cash transaction valued at Near US$13.1 million
MT
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement
AQ
Reunion Neuroscience Inc.(NasdaqGS:REUN) dropped from NASDAQ Composite Index
CI
MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. in a going private transaction.
CI
REUNION NEUROSCIENCE OBTAINS FINAL COURT ORDER FOR PROPOSED PLAN OF ARRANGEMENT
AQ
Reunion Neuroscience Gets Ontario Court's Final Approval for Acquisition by MPM BioImpact
MT
Reunion Neuroscience Brief: Adds In "Assuming Remaining Conditions Precedent Are Satisfied Or Waived", Anticipates Closing of Arrangement Will Occur On Or About July 21, 2023
MT
Reunion Neuroscience Brief: Says Obtained Final Court Order for Proposed Plan of Arrangement Whereby Affiliates of MPM BioImpact Will Buy REUN In An All-cash Deal Valued at Near US$13.1 Million
MT
Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement
AQ
Reunion Neuroscience Brief: Arrangement remains subject to receipt of a final order of the Ontario Superior Court of Justice (Commercial List); Expected to be completed on or around July 21, 2023
MT
Reunion Neuroscience Brief: Shareholders Approve Proposed Plan of Arrangement Whereby Affiliates of MPM BioImpact Will Buy REUN In An All-cash Tansaction Valued at Near US$13.1 Million
MT
Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement
AQ
Reunion Neuroscience : Annual Information Form For the Fiscal Year Ended March 31, 2023 - Form 6-K
PU
Reunion Reports Q4 Results; Shareholders to Get US$1.12 Cash Per Share From Arrangement Agreement with MPM BioImpact
MT
Reunion Neuroscience Brief: Adds It Presented "Encouraging" Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting
MT
Reunion Neuroscience Brief: Common Holders to Receive Consideration of US$1.12 Per Share in Cash from Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FTRP Stock
  4. FTRP Stock
  5. News Field Trip Health Ltd.